Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

56 results about "Lung tumours" patented technology

Lung cancer diagnostics and therapeutics with mir-660

InactiveUS20160108405A1Microbiological testing/measurementFermentationFavorable prognosisUbiquitin-Protein Ligases
Provided are methods of treating lung cancer in a patient in need thereof. The method includes administration to the patient a composition comprising a therapeutically effective amount of a compound that reduces the expression level of E3 ubiquitin-protein ligase MDM2. The compound in certain instances is a miR-660 miRNA, or a functional variant thereof. The patient in need of treatment in certain instances expresses miR-660 in a lung tissue sample or biological fluid sample at a level lower as compared to a control level derived from a subject or plurality of subjects that do not have lung cancer, or as compared to a control level derived from a lung cancer patient or plurality thereof, that have been given a favorable prognosis; expresses MDM2 at a higher level in a lung tissue sample or biological fluid sample as compared to a control level derived from a subject or plurality of subjects that do not have lung cancer, or as compared to a control level derived from a lung cancer patient or plurality thereof that have been given a favorable prognosis; and / or expresses p53 in a lung tissue sample or a biological fluid sample below a control level derived from a lung tumor tissue sample, or plurality thereof, or a biological fluid sample, or plurality thereof, obtained from a patient that has a favorable lung cancer prognosis; or a control level derived from a healthy subject.
Owner:BIOMIRNA HLDG

Traditional Chinese medicine composition for treating lung malignant tumor and usage thereof

The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating lung malignant tumor and an usage thereof. The traditional Chinese medicine composition comprises powder and preparation. The effective components of the powder include seaweed, semen cassiae , kelp, 10 to 20 radix angelicae dahuricae, fritillaria cirrhosa, alpinia oxyphylla, rhizoma cyperi, poria cocos, radix platycodi, fructus psoraleae and bighead atractylodes rhizome. The effective components of the preparation include clematis chinensis, angelica sinensis, prepared rhizome of rehmannia, oroxylum indicum, radix codonopsis, ligusticum wallichii, glossy privet fruit, astragalus, the root of red-rooted salvia and achyranthis bidentatae. The traditional Chinese medicine composition has the advantages that the powder and preparation are used interchangeably and drug properties are complementary to each other, and has the effects of benefiting qi and resolving blood stasis, clearing heat and removing toxicity, nourishing yin and moisturizing lung and relieving cough and reducing sputum, can inhibit the growth of tumor cells while improving the immune resistance of the organism, and has a good healing effect on lung tumor, especially for early-stage cancer and the cure rate is more than 95%. Taking the traditional Chinese medicine composition has the advantages of quick effect, short treatment course, low cost, and has no side effect.
Owner:云南上工中医中药研究院集团有限公司

Method for Manufacturing Animal Model for Researching Pulmonary Tumor and Use Thereof

The present invention is a method for manufacturing an animal model for researching a pulmonary tumor and a use thereof. A transgenic non-human animal of the present invention is prepared by embryonic gene microinjection and possesses a tissue-specific expression of vascular endothelial growth factor A165 (VEGF-A165) in lung. Through the expression of vascular endothelial growth factor A165, the lung cells in the transgenic non-human animal of the present invention have inflammatory, vascularogenesis and angiogenesis responses or induce lung tumors. Thus, the non-human animal of the present invention can serve as an animal model for analyzing the regulation and the anti-tumor drugs screening of pulmonary adenocarcinoma.
Owner:NATIONAL CHUNG HSING UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products